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Abstract
Background Most NSAIDs are thought to be able to
cause hepatic injury and acute liver failure (ALF), but the
event rates of those leading to transplantation (ALFT)
remain uncertain.
Objectives The aim of the study was to estimate popu-
lation event rates for NSAID-associated ALFT
Methods This was a case-population study of ALFT in 57
eligible liver transplant centres in seven countries (France,
Greece, Ireland, Italy, The Netherlands, Portugal and the
UK). Cases were all adults registered from 2005 to 2007
for a liver transplant following ALFT without identified
clinical aetiology, exposed to an NSAID or paracetamol
(acetaminophen) within 30 days before the onset of clinical
symptoms. NSAID and paracetamol population exposures
were assessed using national sales data from Interconti-
nental Marketing Services (IMS). Risk was estimated as
the rate of ALFT per million treatment-years (MTY).
Results In the 52 participating centres, 9479 patients were
registered for transplantation, with 600 for ALFT, 301 of
whom, without clinical aetiology, had been exposed to a
drug within 30 days. Of these 301 patients, 40 had been
exposed to an NSAID and 192 to paracetamol (81 of whom
were without overdose).
Event rates per MTY were 1.59 (95 % CI 1.1–2.2) for all
NSAIDs pooled, 2.3 (95 % CI 1.2–3.9) for ibuprofen, 1.9
(95 % CI 0.8–3.7) for nimesulide, 1.6 (95 % CI 0.6–3.4)
for diclofenac and 1.6 (95 % CI 0.3–4.5) for ketoprofen.
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For paracetamol, the event rate was 3.3 per MTY (95 % CI
2.6–4.1) without overdoses and 7.8 (95 % CI 6.8–9.0)
including overdoses.
Conclusions ALF leading to registration for transplanta-
tion after exposure to an NSAID was rare, with no major
difference between NSAID. Non-overdose paracetamol-
exposed liver failure was twice more common than
NSAID-exposed liver failure.
1 Background
Acute liver injury is one of the more common reasons for
withdrawal of drugs from the market, or for interruption of
their development [1–3]. NSAIDs have often been
involved in liver injury [1, 4], and adverse hepatic reactions
have been reported for most NSAIDs [5]. However, general
population studies have not found a clear difference
between NSAIDs for hepatic reactions not leading to
transplantation [6, 7]. Because of clusters of spontaneous
reports of suspected hepatotoxicity with nimesulide, the
European Medicines Agency’s (EMA) Committee on
Human Medicinal Products (CHMP) required an epide-
miological study of NSAID-exposed acute liver failures
(ALF) leading to transplantation (ALFT).
The objective of the SALT (Study of Acute Liver
Transplantation) study, conducted in seven European
countries (France, Greece, Ireland, Italy, The Netherlands,
Portugal and the UK), was therefore to assess the popula-
tion rates of ALFT without identified clinical aetiology in
patients exposed to NSAIDs.
2 Patients and Methods
The SALT study was a multicentre, multinational, case-
population study [8] conducted in seven countries, and
designed to provide estimates of the population rates of
registration on transplantation lists for ALFT patients
exposed to an NSAID or paracetamol (acetaminophen)
within 30 days before the onset of clinical symptoms of
liver disease (index date).
The study protocol was approved by the CHMP, the data
protections authorities in each of the seven countries, and
by Ethics Committees and Research and Development
(R&D) committees as required [9]. The study period for
inclusion in the liver transplant registries was 2005–2007,
the 3-year period preceding the last nimesulide referral to
regulatory authorities. Data were collected from January
2009 to October 2011.
2.1 Centres and Cases
All 62 liver transplantation centres in the seven countries
were identified. Centres dealing exclusively with cancer (one
centre) or children (four centres) were excluded. The 57
eligible centres were contacted for participation. In partici-
pating centres, all adults (C18 years of age) who were resi-
dent in the country and registered on the liver transplantation
waiting lists during the 3-year study period were identified.
National computerized registries were used in France, Ire-
land, The Netherlands and the UK for case identification, and
centre registries were used for the three other countries.
Anonymized information (sex, age, country resident, liver
disease history and histopathology) was extracted for all
patients and recorded from medical files by trained clinical
research assistants, to separate chronic liver failure (CLF)
from ALFT [10–12]. ALFT status was verified by the local
transplant centre hepatologist, and validated by a national
case classification hepatologist. For all ALFT cases, symp-
toms and dates, laboratory results, viral workups, autoanti-
bodies, concomitant factors and diseases that could help to
identify clinically relevant aetiologies, and drug exposure
history were extracted from all available data and verified by
the local hepatologist. Relevant documents were anony-
mized and scanned for further reference. Data were then
reviewed and validated by the national case classification
hepatologist, who also defined the date of onset of liver
disease (index date) and classified patients as ALFT with or
without an identified clinical aetiology. Typical identified
clinical aetiologies were viral or autoimmune hepatitis,
mushroom toxicity, vascular causes and other, as described
in the medical charts. Cases with clinically defined aetiolo-
gies were not further explored for drug exposure.
In cases without clinically defined aetiologies, drug
exposure, including herbals and homoeopathic medicines,
was ascertained from the patient’s medical files, including
plasma drug concentrations if available. The timing of drug
ingestion or exposure was compared with the index date, to
qualify the exposure as started after the index date (drug
excluded), or taken before the index date, within 7, 15, 30 or
90 days, according to international causality consensus
conference criteria [13–16]. Cases without clinically
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defined aetiology were then classified into (i) not exposed to
drugs within 30 days before the index date; (ii) exposed to
any drug within 30 days before the index date, without drug
overdose; and (iii) acute drug overdose, with or without
suicidal intent, with demonstrated high plasma drug con-
centrations or documented and quantified overdose. Other
exposure-time windows (90, 15 and 7 days before the index
date) were used for sensitivity analyses.
Paracetamol overdoses were confirmed by the case
adjudication committee, based on case description of
documented overdosing (number of tablets reported taken,
empty packs found with the patient, patient or family report
of voluntary overdose, etc.) and/or toxic plasma paraceta-
mol concentrations found. All other cases where paracet-
amol use was identified within 30 days before the index
date were considered as non-overdose.
2.2 Population Exposure
Intercontinental Medical Services Ltd (IMS; London, UK)
provided per-country population exposure to NSAIDs and
paracetamol. These data do not include point-of-sale general
outlet data for the UK, Ireland and The Netherlands. Popu-
lation exposure was described as the number of units and
number of defined daily doses (DDD) [17] sold in each
country over the 3-year period, and as treatment-years
determined from the observed average daily dose as reported
by prescription panels. Purely paediatric formulations were
excluded and parenteral preparations were included. The
IMS data were adjusted to the contribution of non-partici-
pating centres to overall transplantation activity in each
country, as determined from the transplantation registries.
Fixed-dose associations of NSAIDs (e.g. diclofenac ?
misoprostol) or paracetamol (e.g. paracetamol ? codeine)
were attributed to the main component of interest (NSAID or
paracetamol). When paracetamol was associated with an
NSAID (e.g. fixed-dose paracetamol ? ibuprofen), the
cases and sales were attributed to both drugs.
Event rates are reported as the number of cases per
billion DDD, and as the number of cases per million
patient-years of treatment, with exact 95 % Poisson con-
fidence intervals (95 % CI).
All statistical analyses were performed using SAS
software (SAS Institute, NC, USA), version 9.1.
Fig. 1 Patient disposition in the SALT study. Drug exposure (NSAID or other) was considered within 30 days before date of first clinical
symptoms. ALFT acute liver failure leading to transplantation, CLF chronic liver failure
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3 Results
3.1 Participating Centres
Of 57 eligible centres, 54 (94.7 %) agreed to participate:
20/21 in France, 19/20 in Italy, 2/2 in Greece, 3/3 in The
Netherlands, 2/3 in Portugal, 1/1 in Ireland and 7/7 in the
UK. No specific reason was given for non-participation,
other than excess workload. One centre in the UK and one
in Italy that had initially accepted to participate could not
provide data within the study timeframe [9].
3.2 Acute Liver Failure Cases
In the 52 contributing centres (91.2 %), 9479 patients on
liver transplantation waiting lists were identified (Fig. 1),
representing over 90 % of such patients in these countries.
Medical files were not available for 41 patients (0.4 %),
8838 patients (93.2 %) were listed for CLF and 600 (6.3 %)
for ALFT. Among the ALFT patients, the medical files were
missing or incomplete for 18 patients (3.0 %) and case
characteristics could not be ascertained for these 18
patients. In 219 cases (36.5 %), ALFT was explained by a
defined clinical aetiology. These cases were not further
explored for drug exposure. These clinical aetiologies were
viral hepatitis B (34.7 %), autoimmune hepatitis (18.3 %),
other viruses (7.3 %), mushroom toxicity (6.0 %), Wilson’s
disease (5.5 %), arterial thrombosis or Budd–Chiari syn-
drome (6.8 %) and various other causes (e.g. acute alcoholic
or post-traumatic). Clinical aetiologies were not found in
363 cases, which were considered as clinically unexplained.
Overall, 187 non-overdose cases had been exposed to at
least one drug within 30 days before the index date: 40 to at
least one NSAID and 147 to drugs other than NSAIDs.
Two-thirds were female, mean age was around 40 years and
over 81 % were eventually transplanted (Table 1). ALFT
was attributed to overdose in 114 cases. In 62 cases no drug
exposure was found within 30 days before the index date.
3.3 NSAID- and Paracetamol-Exposed Cases
Overall, 40 cases had been exposed to a total of 43 NSAIDs
within 30 days before the index date. One case had been
exposed only to topical diclofenac (Table 2). Thirty-five
had also been exposed to other drugs, including paraceta-
mol in 22 cases (55.0 %; Table 1). Of the 147 non-NSAID
and non-overdose cases, another 59 (40.1 %) had been
exposed to non-overdose paracetamol within 30 days
before the index date.
Overall, 111 (97.4 %) of the 114 overdoses were
attributed to paracetamol.
3.4 Event Rates
The overall NSAID event rate was 1.59 (95 % CI
1.14–2.17) ALFT cases per million treatment-years
Table 1 Demographic characteristics of patients registered to transplantation waiting lists for acute liver failure exposed to drugs within 30 days
of index date, in seven European countries (2005–2007)
Patient characteristics With C1 NSAID
(n = 40)
Without NSAID
(n = 147)
Acute drug
overdose (n = 114)
Total
(n = 301)
Male [n (%)] 11 (27.5) 48 (32.7) 44 (38.6) 103 (34.2)
Mean age at registration on transplant list [years (SD)] 43.9 (14.6) 39.1 (12.5) 33.6 (10.9) 37.7 (12.7)
Transplanted [n (%)] 34 (85.0) 127 (86.4) 83 (72.8) 244 (81.1)
Exposed to NSAID B30 days before index date [n (%)] 40 (100.0) 0 (0.0) 11 (9.6) 51 (16.9)
Exposed to paracetamol (acetaminophen) or paracetamol
combinations B30 days before index date [n (%)]
22 (55.0) 59 (40.1) 111 (97.4) 192 (63.8)
Exposed to drugs other than NSAIDs B30 days
before index date [n (%)]
35 (87.5) 147 (100.0) 114 (100.0) 296 (98.3)
Table 2 Number of patients with acute liver failure leading to
transplantation exposed to various NSAIDs as a function of time
before first symptoms
NSAID 90 days
(n = 44
cases)
30 days
(n = 40
cases)
15 days
(n = 37
cases)
7 days
(n = 34
cases)
Celecoxib 2 2 2 1
Diclofenaca 7 6 5 5
Etodolac 2 2 2 2
Ibuprofen 14 13 11 11
Indometacin 1 1 1 1
Ketoprofen 3 3 3 3
Ketorolac 2 2 2 1
Meloxicam 1 0 0 0
Naproxen 2 2 2 2
Niflumic acid 1 1 1 1
Nimesulide 9 8 7 6
NSAID unspecified 3 3 3 2
All exposures 47 43 39 35
a One case with diclofenac in topical form
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(MTY), corresponding to 4.37 cases per billion DDD, with
no significant difference between individual NSAID
(Fig. 2). The common NSAIDs celecoxib, diclofenac,
ibuprofen, ketoprofen, naproxen and nimesulide all had
point estimates below 10 per MTY or per billion DDD, and
an upper limit of the 95 % CI below 5 per MTY, except for
naproxen (5.89) and celecoxib (7.79). Event rates for all
NSAIDs pooled were almost four times higher in Ireland
than in all countries pooled (Table 3).
Over the same period, 192 cases had been exposed to
paracetamol within 30 days before the index date, 81 of
which were without overdose, resulting in ALFT rates of
3.31 (95 % CI 2.63–4.11) per MTY for non-overdose
paracetamol and 7.84 (95 % CI 6.77–9.04) per MTY when
overdoses were included (Fig. 2). CIs did not overlap with
those of event rates for all NSAIDs pooled.
These results remained consistent over the sensitivity
analyses, such as increasing the exposure window to
90 days or reducing it to 15 or 7 days, removing NSAID-
exposed cases also exposed to paracetamol or including
cases with paracetamol overdose that had also been
exposed to NSAIDs (data not shown).
Among the 147 ALFT cases not exposed to an NSAID,
the most commonly found drug was paracetamol (40.1 %),
followed by psycholeptics (Anatomical Therapeutic
Chemical [ATC] class N05; 15.6 %) and antidepressants
(ATC code N06A; 7.5 %). Cannabis was found in ten cases
(6.8 %) and herbals found in seven cases (4.8 %). Other
drugs mentioned include rifampicin (rifampin) and/or other
antituberculosis agents, amoxicillin or omeprazole.
4 Discussion
This case-population study of liver transplant in over 227
million inhabitants could not demonstrate clearly different
severe liver toxicity between the mainstream NSAIDs, and
the upper limits of the 95% CIs, which indicate the greatest
risk that one could confidently exclude, were similar. These
results reproduce and confirm the results of population
studies of less severe hepatic reactions [6, 7]. This study was
not designed to look at ALF not listed for transplantation.
The main strength of the study is that all cases of ALF
listed for transplantation are registered on transplantation
lists, whether the transplant was actually done or not. Per-
country identification of cases can therefore be complete.
This is a prerequisite for a case-population approach [8],
and allows a measure of absolute risk. Participating centres
represented over 90 % of all liver transplant units in the
countries considered. The number of potential cases in non-
participating centres was known from national or local
registries, which allowed the adjustment of exposure data.
Fig. 2 Forest plot and event rates for exposure to an NSAID or
paracetamol (acetaminophen) [non-overdose only, or all cases
including intentional and non-intentional overdose] within 30 days
before the date of the first clinical symptoms. DDD defined daily
doses, IMS Intercontinental Medical Services Ltd
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Transplantations are performed only in selected and
accredited centres, with expert hepatologists who are very
cognizant of liver failure. We are therefore confident not to
have missed any of our target cases (ALF leading to reg-
istration for transplantation) and to have the best infor-
mation available on causes and exposures.
This was a study of only ALF cases that led to regis-
tration for transplantation, not of all ALF. Cases not reg-
istered for transplantation might correspond to patients
older than the age limit of transplantation, which is a
potential limitation of our study, or patients who die before
they can be listed for transplantation or who are not con-
sidered for transplantation for other reasons. If the reason
for not transplanting is not related to exposure to the drugs
of interest, missing these cases that might have been reg-
istered for transplantation but that were not transplanted
would decrease the overall study power, but would not bias
the results. Since the drugs were all in the same therapeutic
class, it is unlikely that differential exposure to any indi-
vidual drug would be a reason to decide to transplant or not
to transplant a patient. The multi-country nature of the
study can also compensate for any country-specific drug-
related bias.
Other studies have included patients with less-severe
ALF and found similar results to ours [6, 7]. Because less-
severe hepatic injuries might be hospitalized in many dif-
ferent settings, there is no possibility of the exhaustive
countrywide retrieval of cases that are necessary for the
case-population design used here.
Under-ascertainment of actual drug exposure in patients,
related to poor history taking in transplant centres, might
spuriously decrease the numerator. The medical history of
liver transplant patients is usually thoroughly explored
before transplantation, including information from general
practitioners (GPs) and other sources. For confidentiality
reasons, we could not seek further information from GPs or
patients; however, from our expert board it is unlikely that
relevant information from the GP would be missing from
the hospital files. Nevertheless, patients may have had
exposures or diseases unknown to the GP [18–20]. This
might be especially true for over-the-counter (OTC) drugs
such as paracetamol or ibuprofen. This could artificially
reduce the event rates for these drugs, but would not
change the findings of the study concerning prescription
NSAIDs.
Facing an otherwise unexplained ALF, clinicians might
tend to look for evidence of exposure to ‘known’ hepato-
toxic drugs such as nimesulide, diclofenac or paracetamol
more than exposure to other drugs, including other NSAIDs.
These may then be under-ascertained and bias the result in
disfavour of known hepatotoxic drugs (notoriety bias). On
the other hand, because adverse hepatic reactions have been
reported for many NSAIDs [5], there is little reason that any
one would have been reported more or less often than
others. For paracetamol, the uncertainty lies between
underreporting of OTC paracetamol and the search for
hepatotoxic drugs. Underreporting of OTC use would
reduce the apparent risk of paracetamol, which in this study
would be a conservative bias and could not explain the
2-fold higher event association with paracetamol.
The choice of the 30-day exposure window was based on
causality assessment methods from consensus conferences
[13–15], which state that it would be very unlikely that a
drug stopped more than 30 days before the onset of first
symptoms might be associated with acute hepatotoxicity,
especially since NSAIDs such as ibuprofen, diclofenac or
nimesulide have half-lives ranging from 2 to 8 hours.
Treatment duration was very rarely recorded, even for
those patients who were still on the medication at the time
of symptom onset, so we cannot describe a duration-of-
treatment effect. Considering the small number of cases
with individual drugs, it might have been unwise to attempt
any kind of systematic case description. This should
probably come from studies of less severe but more fre-
quent cases. This assumes that the different NSAIDs
included in the analysis were expected to be used in
Table 3 Per-country incidence rates of acute liver failure leading to transplantation exposed to any NSAID within 30 days before index date in
seven European countries (2005–2007). Exposure is adjusted for centre participation
Countries Number of
DDD (IMS)
Number of
treatment-years
Number of cases
exposed to an NSAID
Cases per billion
DDD over 3 years
Rate per million
treatment-years (95 % CI)
France 2,526,930,718 6,644,920 9 3.56 1.35 (0.62–2.57)
Greece 591,913,320 1,492,625 0 0 0.00 (0.00–2.47)
Ireland 186,340,332 488,393 3 16.1 6.14 (1.27–17.96)
Italy 2,763,378,262 8,942,220 10 3.62 1.12 (0.54–2.06)
Portugal 532,195,161 1,382,853 0 0 0.00 (0.00–2.67)
Netherlands 473,274,972 928,021 4 8.45 4.31 (1.17–11.03)
UK 2,081,819,276 5,212,248 14 6.72 2.69 (1.47–4.51)
Total 9,155,852,040 25,091,279 40 4.37 1.59 (1.14–2.17)
DDD defined daily doses, IMS Intercontinental Medical Services Ltd
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subpopulations with similar risk factors of developing
ALF. Ibuprofen might be used in younger patients for a
shorter duration of time [21], which could contribute to a
lower event rate. The other NSAIDs are used in mostly
similar populations in countries where this information
exists [21, 22].
Because we did not have access to the actual number of
users in each country, we chose to use overall population
exposure measures, in DDD or treatment-years. The same
data source (IMS) was used for all countries and all NSAIDs
or paracetamol. This includes all sales to pharmacies,
including OTC resale, but not sales in supermarkets, con-
venience stores or petrol stations, which are possible in the
UK, Ireland or The Netherlands. These artificially lower
exposures and may result in higher apparent event rates in
these countries for drugs sold in such outlets, mostly ibu-
profen and paracetamol. This would not affect drugs that are
prescription-only in the countries considered, such as dic-
lofenac, ketoprofen or nimesulide. In France, OTC ibu-
profen and paracetamol are sold only in pharmacies, so that
the sales data for these are complete.
Sales data were adjusted for the non-contributing trans-
plantation centres. Since the same source was used for all
drugs in all countries, any distortion would affect all drugs
in the same manner, preserving the internal validity of the
results. Expressing the results per DDD based on theoretical
daily treatment as used for drug statistics, or as patient-years
based on average prescribed dose, does not materially
change the results. In this study we did not have access to
the absolute number of patients treated with individual
drugs, only quantities converted to DDD. This unit provides
a standardized way to measure per country or per capita
drug use that can be compared across and between drugs
and drug families. Treatment-years are calculated from the
average daily dose observed in patient panels in each
country, making them perhaps a better metric because they
take into account different drug prescription patterns
between countries and drugs. If all drugs are used in more or
less the same way, then the treatment-years are directly
related to the number of patients and average prescription,
and treatment-years might be an appropriate proxy for the
number of users. These crude measures have the advantage
of simplicity and robustness, but the inconvenience of being
rather insensitive.
Event rates for NSAIDs were less than ten cases per
million patient-years of treatment or billion DDD sold over
3 years, all NSAIDs combined or for individual drugs,
consistent with other data for fulminant hepatitis [23]. This
makes any attempt to measure more precisely possible
differences among individual NSAIDs very difficult.
Considering the small number of cases, and the very non-
specific nature of liver pathology at the advanced stage of
liver failure in these patients, it was not possible to identify
specific pathological features, risk factors for one or other
of the NSAIDs, or elements suggesting mechanisms of
severe liver injury. From other studies, no specific mech-
anism of toxicity has been identified for individual NSAIDs
other than diclofenac and sulindac [24–27]. Nevertheless,
these two drugs did not seem to be associated with excess
risk of hepatotoxicity in the present study. In other regis-
tries of drug-induced liver injury (DILI), antibiotics seem
to be more often associated with DILI than NSAIDs. This
might be related to the recording of less severe toxicity or
cholestatic liver disease not leading to transplantation,
which would not appear in our study. It might also be
related to real differences in drug toxicity between coun-
tries, for unidentified reasons.
We found a 2- to 3-fold higher event rate for non-
overdose paracetamol compared with all NSAIDs pooled,
based on the same criteria used for NSAIDs. This has not
been generally described, paracetamol toxicity being
reported as essentially associated with overdose. There
may be several reasons for this: OTC paracetamol is usu-
ally not recorded in claims databases or in medical dat-
abases; and in field studies there may be under-
ascertainment or dismissal of non-overdose paracetamol
exposure. The hepatotoxicity of paracetamol has been
generally thought to be confined to overdose [3, 28, 29],
including staggered overdoses [30], although there have
been studies showing an association of paracetamol at
therapeutic doses and liver injury [3, 31, 32] in addition to
case reports [33]. Others dispute this association [34–36].
We found paracetamol in 40 % of the cases of ALFT
where any drug was found during the 30 days before the
first symptoms (more often than any other drug). When this
is compared with population exposure, in DDD or treat-
ment-years, the event rates were 2- to 3-fold greater than
with NSAIDs. This may be purely coincidental, and in
most cases there may be another explanation [35], but non-
overdose paracetamol might also play a direct or indirect
causal role [31, 33], maybe through depletion of glutathi-
one, reducing liver detoxification capabilities [37, 38].
Because paracetamol may be bought OTC in supermarkets
and petrol stations (albeit in very small quantities), and this
would not be captured in the UK, Ireland or The Nether-
lands, there could be concern about overestimation of the
event rate for paracetamol. However, considering the event
rate differential with all NSAIDS, the fraction thus missed
would have to be half of the overall sales of all seven
countries to explain the difference in event rates between
paracetamol and all NSAIDs pooled. Such a hypothesis
would appear to be somewhat far-fetched, especially since
in other countries all sales are captured.
Because patients in pain require medication to alleviate
the pain, the choice is not really between NSAID and no
medication, but between one analgesic and another. In this
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case, avoiding any one of the mainstream NSAIDs because
of excess reporting of liver toxicity would shift the use and
risk to another NSAID. This would probably not change
the individual per-patient risk of severe hepatic failure,
which is essentially the same for the mainstream NSAIDs.
Shifting to paracetamol might actually double the risk of
ALF, even when overdose is not considered.
5 Conclusion
From this seven-country, 3-year, case-population study of
ALF leading to registration on transplantation lists, it
appears that the presence of an NSAID within 1 month
before the first symptoms of ALFT is rare, and that there is
evidence of a relevant difference between the different
mainstream NSAIDs for population-time exposure rates.
The event rate of ALFT exposed to non-overdose para-
cetamol was more than 2-fold higher than for all NSAIDs
pooled, and higher than most individual NSAIDs.
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